文献速递贫血与红细胞疾病

大剂量静脉铁剂与口服铁剂治疗缺铁性贫血的疗效和安全性比较:多中心、前瞻性、开放标签、随机对照研究

[Comparison of the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia: a multicenter, prospective, open-label, randomized controlled study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

该多中心前瞻性随机对照研究纳入338例缺铁性贫血患者,1∶1分为大剂量静脉铁剂组和口服铁剂组,观察12周。静脉组第4周血红蛋白较基线升高(40.7±17.3)g/L,显著高于口服组(27.2±17.5)g/L(P<0.001),铁代谢参数和疲劳评分早期改善亦更优,总不良反应发生率两组相似。

要点

  • 静脉组第4周血红蛋白较基线升高(40.7±17.3)g/L,显著高于口服组(27.2±17.5)g/L(P<0.001)。
  • 静脉组血清铁、转铁蛋白饱和度、总铁结合力、血清铁蛋白第4周较基线改善均明显优于口服组(P<0.001)。
  • 两组总不良反应发生率相似:静脉组3.5%(6/169)对口服组5.9%(10/169),P=0.442。

核心结论

  • 大剂量静脉铁剂可实现血红蛋白早期迅速提升,快速改善血清铁、转铁蛋白饱和度、总铁结合力、血清铁蛋白及患者疲劳评分,患者耐受性良好。

研究设计与样本

  • 多中心、前瞻性、开放标签、随机对照研究(1∶1),于2022年6月1日至2024年1月19日在苏州大学附属第一医院、苏州弘慈血液病医院及淮安市第二人民医院纳入338例缺铁性贫血患者。
  • 静脉组169例接受大剂量静脉铁剂治疗,口服组169例接受口服铁剂治疗,观察12周。

主要发现

  • 4周时静脉组血红蛋白由(76.8±15.0)g/L升至(118.0±13.3)g/L,口服组由(77.9±11.6)g/L升至(104.3±15.0)g/L。
  • 静脉组血红蛋白较基线升高(40.7±17.3)g/L,显著高于口服组(27.2±17.5)g/L(P<0.001)。
  • 静脉组血清铁、转铁蛋白饱和度、总铁结合力、血清铁蛋白第4周较基线改善均明显优于口服组(P<0.001)。
  • 静脉组早期疲劳评分改善明显优于口服组(P<0.001)。
  • 总不良反应发生率静脉组3.5%(6/169)对口服组5.9%(10/169),P=0.442。

关键数值与推荐

  • 主要研究终点为血红蛋白从基线到第4周的变化。
  • 次要研究终点为血红蛋白第8、12周的变化,铁代谢参数从基线到第4周的变化及疲劳评分从基线到第4、8周的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to compare the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia (IDA) . Methods: This prospective randomized controlled study (1∶1) enrolled 338 patients with IDA at The First Affiliated Hospital of Soochow University, Suzhou Hongci Hematology Hospital, and Huai'an Second People's Hospital from June 1, 2022, to January 19, 2024. Of all the patients, 169 received high-dose intravenous iron therapy and 169 received oral iron treatment for 12 weeks of observation. Focus on the hemoglobin (HGB) change from baseline to week 4, secondary focus was on the HGB and iron metabolism parameters (serum iron [SI], transferrin saturation [TSAT], total iron binding force [TIBC], serum ferritin [SF]), and changes in the fatigue score, efficacy, and treatment-related adverse effects were monitored throughout in the two treatment groups. Results: The HGB levels were improved in both treatments, but the HGB improved faster in the intravenous group compared with the oral group. HGB increased from (76.8±15.0) g/L to (118.0±13.3) g/L in the intravenous group and from (77.9±11.6) g/L to (104.3±15.0) g/L in the oral group after 4 weeks of treatment. The increase from baseline in the intravenous group (40.7±17.3) g/L was significantly higher than that in the oral group (27.2±17.5) g/L (P<0.001). The intravenous group demonstrated a more significant early effect than the oral group in terms of iron metabolism parameter improvement. SI, TSAT, TBIC, and SF increased better from baseline at 4 weeks in the intravenous group than in the oral group (P<0.001). Additionally, the intravenous group exhibited better fatigue scores for early improvement than the oral group (P<0.001). The incidence of total adverse effects was similar in the intravenous group as compared to the oral group (3.5% [6/169] vs 5.9% [10/169], P=0.442) . Conclusion: High doses of intravenous iron quickly boost HGB early, causing rapid improvement in SI, TSAT, TBIC, SF, and patient fatigue scores. The patient was well tolerated. 目的: 比较大剂量静脉铁剂与口服铁剂治疗缺铁性贫血(IDA)的疗效和安全性。 方法: 前瞻性随机对照(1∶1)入组2022年6月1日至2024年1月19日苏州大学附属第一医院、苏州弘慈血液病医院及淮安市第二人民医院338例缺铁性贫血患者,其中169例接受大剂量静脉铁剂治疗(静脉组),169例接受口服铁剂治疗(口服组),进行12周观察,主要研究终点为HGB从基线到第4周的变化;次要研究终点为HGB第8、12周的变化,铁代谢参数[血清铁(SI)、转铁蛋白饱和度(TSAT)、总铁结合力(TIBC)、血清铁蛋白(SF)]从基线到第4周的变化及疲劳评分从基线到第4、8周的变化。全程监测两个治疗组的疗效及治疗相关不良反应。 结果: HGB水平在两个治疗组中均得到改善,与口服组相比静脉组HGB早期提升更快。4周时,静脉组HGB由(76.8±15.0)g/L升至(118.0±13.3)g/L,口服组由(77.9±11.6)g/L升至(104.3±15.0)g/L。静脉组较基线升高(40.7±17.3)g/L,显著高于口服组(27.2±17.5)g/L(P<0.001)。静脉组比口服组对于改善铁代谢参数的早期效果也更显著,静脉组SI、TSAT、TIBC、SF在4周时较基线改善情况均明显优于口服组(P<0.001)。此外,静脉组对于早期改善患者的疲劳评分亦明显优于口服组(P<0.001)。静脉组与口服组相比总不良反应发生率相似[3.5%(6/169)对5.9%(10/169), P=0.442]。 结论: 大剂量静脉铁剂可以实现HGB早期迅速提升,快速改善SI、TSAT、TBIC、SF及患者疲劳评分,患者耐受性良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Wang H, Zhang YM, et al. [Comparison of the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia: a multicenter, prospective, open-label, randomized controlled study]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39765352. doi:10.3760/cma.j.cn121090-20240424-00161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。